{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:08:38Z","timestamp":1793992118204,"version":"4.8.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jogc.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Obstetrics and Gynaecology Canada"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.jogc.2021.09.011","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T05:29:39Z","timestamp":1637126979000},"page":"1450-1456.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Guideline No. 422f: Menopause and Breast Cancer"],"prefix":"10.1016","volume":"43","author":[{"given":"Michelle","family":"Jacobson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Graves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Wolfman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Fortier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jogc.2021.09.011_bib0001","doi-asserted-by":"crossref","first-page":"E1441","DOI":"10.1503\/cmaj.180463","article-title":"Recommendations on screening for breast cancer in women aged 40-74 years who are not at increased risk for breast cancer","volume":"190","author":"Klarenbach","year":"2018","journal-title":"CMAJ"},{"key":"10.1016\/j.jogc.2021.09.011_bib0002","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/01.SLA.0000059969.64262.87","article-title":"Rating the risk factors for breast cancer","volume":"237","author":"Singletary","year":"2003","journal-title":"Ann Surg"},{"key":"10.1016\/j.jogc.2021.09.011_bib0003","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/GME.0000000000000921","article-title":"The Nams Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of the north american menopause society","volume":"24","year":"2017","journal-title":"Menopause"},{"key":"10.1016\/j.jogc.2021.09.011_bib0004","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1701-2163(15)30487-4","article-title":"Managing menopause","volume":"36","author":"Reid","year":"2014","journal-title":"J Obstet Gynaecol Can"},{"key":"10.1016\/j.jogc.2021.09.011_bib0005","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s10549-014-2934-6","article-title":"Risk of breast cancer after stopping menopausal hormone therapy in the e3n cohort","volume":"145","author":"Fournier","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jogc.2021.09.011_bib0006","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(19)31709-X","article-title":"Collaborative Group on Hormonal Factors in Breast C. Type and timing of menopausal hormone therapy and breast cancer risk: Individual participant meta-analysis of the worldwide epidemiological evidence","volume":"394","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jogc.2021.09.011_bib0007","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1001\/jama.2020.9482","article-title":"Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the women's health initiative randomized clinical trials","volume":"324","author":"Chlebowski","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jogc.2021.09.011_bib0008","doi-asserted-by":"crossref","first-page":"m3873","DOI":"10.1136\/bmj.m3873","article-title":"Use of hormone replacement therapy and risk of breast cancer: Nested case-control studies using the qresearch and cprd databases","volume":"371","author":"Vinogradova","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.jogc.2021.09.011_bib0009","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1093\/humrep\/dei085","article-title":"Levonorgestrel intrauterine system (lng-ius) with conjugated oral equine estrogen: A successful regimen for hrt in perimenopausal women","volume":"20","author":"Hampton","year":"2005","journal-title":"Hum Reprod"},{"key":"10.1016\/j.jogc.2021.09.011_bib0010","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1056\/NEJMoa1700732","article-title":"Contemporary hormonal contraception and the risk of breast cancer","volume":"377","author":"Morch","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jogc.2021.09.011_bib0011","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1097\/AOG.0b013e31828c5974","article-title":"Breast effects of bazedoxifene-conjugated estrogens: A randomized controlled trial","volume":"121","author":"Pinkerton","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jogc.2021.09.011_bib0012","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/ijc.31401","article-title":"Effect of a tissue selective estrogen complex on breast cancer: Role of unique properties of conjugated equine estrogen","volume":"143","author":"Yue","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jogc.2021.09.011_bib0013","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejca.2012.07.003","article-title":"Hormone replacement therapy after breast cancer: 10 year follow up of the stockholm randomised trial","volume":"49","author":"Fahlen","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jogc.2021.09.011_bib0014","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0140-6736(04)15493-7","article-title":"Habits (hormonal replacement therapy after breast cancer\u2013is it safe?), a randomised comparison: Trial stopped","volume":"363","author":"Holmberg","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jogc.2021.09.011_bib0015","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1186\/bcr3097","article-title":"Tibolone increases bone mineral density but also relapse in breast cancer survivors: Liberate trial bone substudy","volume":"14","author":"Bundred","year":"2012","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.jogc.2021.09.011_bib0016","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ctrv.2016.11.012","article-title":"Management of hot flashes in women with breast cancer receiving ovarian function suppression","volume":"52","author":"Leon-Ferre","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jogc.2021.09.011_bib0017","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1200\/JCO.2010.29.9230","article-title":"Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors","volume":"28","author":"Bordeleau","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jogc.2021.09.011_bib0018","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1200\/JCO.2015.60.9412","article-title":"Electroacupuncture versus gabapentin for hot flashes among breast cancer survivors: A randomized placebo-controlled trial","volume":"33","author":"Mao","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jogc.2021.09.011_bib0019","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/GME.0000000000000779","article-title":"Comparative effectiveness of electro-acupuncture versus gabapentin for sleep disturbances in breast cancer survivors with hot flashes: A randomized trial","volume":"24","author":"Garland","year":"2017","journal-title":"Menopause"},{"key":"10.1016\/j.jogc.2021.09.011_bib0020","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2217\/WHE.14.3","article-title":"Paroxetine: A first for selective serotonin reuptake inhibitors - a new use: Approved for vasomotor symptoms in postmenopausal women","volume":"10","author":"Weber","year":"2014","journal-title":"Womens Health (Lond)"},{"key":"10.1016\/j.jogc.2021.09.011_bib0021","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1097\/GME.0000000000000773","article-title":"Extended-release oxybutynin therapy for vasomotor symptoms in women: A randomized clinical trial","volume":"23","author":"Simon","year":"2016","journal-title":"Menopause"},{"key":"10.1016\/j.jogc.2021.09.011_bib0022","doi-asserted-by":"crossref","first-page":"pkz088","DOI":"10.1093\/jncics\/pkz088","article-title":"Oxybutynin vs placebo for hot flashes in women with or without breast cancer: A randomized, double-blind clinical trial (ACCRU SC-1603)","volume":"4","author":"Leon-Ferre","year":"2020","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.jogc.2021.09.011_bib0023","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3816\/CBC.2009.n.037","article-title":"Sexual dysfunction and aromatase inhibitor use in survivors of breast cancer","volume":"9","author":"Kwan","year":"2009","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.jogc.2021.09.011_bib0024","first-page":"295","article-title":"An efficient tool for the primary care management of menopause","volume":"63","author":"Goldstein","year":"2017","journal-title":"Can Fam Physician"},{"key":"10.1016\/j.jogc.2021.09.011_bib0025","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/GME.0000000000001121","article-title":"Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: Consensus recommendations from the north american menopause society and the international society for the study of women's sexual health","volume":"25","author":"Faubion","year":"2018","journal-title":"Menopause"},{"key":"10.1016\/j.jogc.2021.09.011_bib0026","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jamainternmed.2018.0116","article-title":"Efficacy of vaginal estradiol or vaginal moisturizer vs placebo for treating postmenopausal vulvovaginal symptoms: A randomized clinical trial","volume":"178","author":"Mitchell","year":"2018","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jogc.2021.09.011_bib0027","unstructured":"Serum estradiol levels in postmenopausal women with breast cancer receiving adjuvant aromatase inhibitors and vaginal estrogen. Clinicaltrials.Gov identifier: Nct00984399."},{"key":"10.1016\/j.jogc.2021.09.011_bib0028","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/jnci\/93.10.754","article-title":"Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality","volume":"93","author":"O'Meara","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jogc.2021.09.011_bib0029","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/cmt.5.2.151.155","article-title":"Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: A cohort study","volume":"5","author":"Dew","year":"2002","journal-title":"Climacteric"},{"key":"10.1016\/j.jogc.2021.09.011_bib0030","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10549-012-2198-y","article-title":"Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: A nested case-control study","volume":"135","author":"Le Ray","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jogc.2021.09.011_bib0031","first-page":"643","article-title":"Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (alliance)","volume":"26","author":"Barton","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jogc.2021.09.011_bib0032","doi-asserted-by":"crossref","first-page":"R881","DOI":"10.1186\/bcr1317","article-title":"Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ","volume":"7","author":"Namba","year":"2005","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.jogc.2021.09.011_bib0033","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0960-0760(01)00066-8","article-title":"In vitro and in vivo biologic effects of ospemifene (FC-1271a) in breast cancer","volume":"77","author":"Taras","year":"2001","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.jogc.2021.09.011_bib0034","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.jogc.2018.05.046","article-title":"366-Gynaecologic management of hereditary breast and ovarian cancer","volume":"40","author":"Jacobson","year":"2018","journal-title":"J Obstet Gynaecol Can"},{"key":"10.1016\/j.jogc.2021.09.011_bib0035","doi-asserted-by":"crossref","first-page":"7804","DOI":"10.1200\/JCO.2004.00.8151","article-title":"Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: The prose study group","volume":"23","author":"Rebbeck","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jogc.2021.09.011_bib0036","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/jnci\/djn313","article-title":"Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers","volume":"100","author":"Eisen","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jogc.2021.09.011_bib0037","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jamaoncol.2018.0211","article-title":"Hormone replacement therapy after oophorectomy and breast cancer risk among BRCA1 mutation carriers","volume":"4","author":"Kotsopoulos","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jogc.2021.09.011_bib0038","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.critrevonc.2018.09.018","article-title":"Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis","volume":"132","author":"Marchetti","year":"2018","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Journal of Obstetrics and Gynaecology Canada"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1701216321007477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1701216321007477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T15:39:37Z","timestamp":1761665977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1701216321007477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S1701216321007477"],"URL":"https:\/\/doi.org\/10.1016\/j.jogc.2021.09.011","relation":{},"ISSN":["1701-2163"],"issn-type":[{"value":"1701-2163","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Guideline No. 422f: Menopause and Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Obstetrics and Gynaecology Canada","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jogc.2021.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Society of Obstetricians and Gynaecologists of Canada\/La Soci\u00e9t\u00e9 des obst\u00e9triciens et gyn\u00e9cologues du Canada. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}